Navigating the Adverse Effects of ADT: Improving Patient Outcomes (17231 Live Symposium)
This educational program will equip urologists, medical oncologists, radiation oncologists, and other healthcare providers involved in the treatment of patients who might undergo or have undergone androgen deprivation therapy (ADT) with the up-to-date clinical knowledge and tools they need to best diagnose and treat their patients and adverse effects they may face.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical College of Wisconsin and (name of non-accredited provider). The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation
The Medical College of Wisconsin designates this activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from Ferring Pharmaceuticals.
This program is fully compliant with ADA regulations. Please contact us at 434-817-2000 to make special arrangements for this program.
Target Audience
This program will be physician-led and designed for urologists, medical oncologists, radiation oncologists, and other healthcare providers involved in the treatment of patients who might undergo or have undergone androgen deprivation therapy (ADT).
Learning Objectives
- Evaluate the recommendations for current use and mechanisms of actions of ADT options for prostate cancer treatment
- Identify the effects of ADT on quality of life
- Address the impact of ADT on bone loss and related side effects
- Assess the research evidence showing cardiovascular and metabolic risks caused by ADT therapy in advanced prostate cancer patients
The Boston Convention Center
Room 205BC, Meeting Level 2
Boston, Massachusetts
Faculty and Planner Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
E. David Crawford, MD discloses the following relevant financial relationships:
Served as a consultant or advisor for: Dendreon, Ferring, Genomic Health, Janssen, MDx
Served as a consultant or advisor, meeting participant or lecturer for: Bayer
Received grants for clinical research from: NIH, University of Colorado Cancer Center
His wife is an employee of Dendreon
Thomas E. Keane, MBBCh discloses the following relevant financial relationships:
Served as a consultant for: Bayer, Ferring, Janssen
Jehonathan H. Pinthus, MD, PhD discloses the following relevant financial relationship:
Served as a speaker for: Ferring
Neal D. Shore, MD discloses the following relevant financial relationships:
Served as a consultant for: Amgen, AbbVie, Astellas, Bayer, Dendreon, Ferring, Janssen, Medivation, Sanofi, Tolmar
The educational content of this program has been peer reviewed by The Medical College of Wisconsin. The Medical College of Wisconsin and Carden Jennings Publishing report the following relationship(s): No relevant financial relationships to disclose. Signed disclosures are on file at The Medical College of Wisconsin.
Available Credit
- 1.50 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.50 Hours of ParticipationHours of Participation credit.